Glass House Brands (GLAS) Capital Expenditures (2020 - 2026)
Glass House Brands' (GLAS) quarterly Capital Expenditures came in at -$3.5 million in Q1 2026, up 47.04% year-on-year from -$2.4 million in Q1 2025, and down 116.62% on a QoQ basis from $21.3 million in Q4 2025.
Glass House Brands (GLAS) Capital Expenditures (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Capital Expenditures data on file, last reported at -$3.5 million in Q1 2026.
- On a quarterly basis, Capital Expenditures rose 47.04% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was -$293000.0, a 104.88% decrease from a year earlier, with the FY2025 full-year figure at -$3.4 million, down 133.44% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$3.5 million, down from $21.3 million in the prior quarter.
- Over the last five years, Capital Expenditures for GLAS reached as high as $21.3 million in Q4 2025 and fell as low as -$9.5 million in Q2 2025.
- Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of -$1.4 million in 2024.
- Across the five-year window, Capital Expenditures soared 1404.77% in 2022 and slumped 1999.03% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $4.1 million in 2022, then soared by 47.85% to $6.0 million in 2023, then soared by 198.35% to $18.0 million in 2024, then gained by 18.35% to $21.3 million in 2025, then sank by 116.62% to -$3.5 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$3.5 million in Q1 2026, $21.3 million in Q4 2025, and -$8.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 99.60 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.55 Mn |
| Mar 31, 2026 | -3.55 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Sep 30, 2025 | -8.63 Mn |
| Sep 30, 2025 | -8.63 Mn |
| Jun 30, 2025 | -9.46 Mn |
| Jun 30, 2025 | -9.46 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Dec 31, 2024 | 18.03 Mn |
| Dec 31, 2024 | 18.03 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | 6.04 Mn |
| Dec 31, 2023 | 6.04 Mn |